PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

▤ Summary

PDS Biotech reported third-quarter 2025 results and gave a detailed update on its clinical programs. The company said its VERSATILE-002 phase 2 trial is complete and that the data support an effort to seek an accelerated approval path in the ongoing VERSATILE-003 phase 3 study. It also highlighted new NCI clinical data on its immunotherapy platforms and preliminary colorectal cancer results for PDS01ADC that met criteria for expansion. Financially, the company narrowed its quarterly net loss and ended the period with $26.2 million in cash, while also raising about $5.3 million through a recent stock and warrant sale.

▦ Linked Companies